Repros data highlights pain relief in Proellex trial

An interim analysis of mid-stage data on Repros' lead therapy Proellex revealed a statistically significant reduction in pain among women suffering from endometriosis. There were no significant differences in response to either the 25 mg or 50 mg dose of the drug and researchers say that most side effects were mild.

- read the release

Suggested Articles

Dewpoint Therapeutics aims to advance research in one of the more mysterious cell organelles: biomolecular condensates.

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.